PDF(Pubmed)
Abstract：
UNASSIGNED: The cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is involved in the progression of various cancers, but its biological roles in breast cancer (BRCA) remain unclear. Therefore, we performed a systematic multiomic analysis to expound on the prognostic value and underlying mechanism of CTLA4 in BRCA.
UNASSIGNED: We assessed the effect of CTLA4 expression on BRCA using a variety of bioinformatics platforms, including Oncomine, GEPIA, UALCAN, PrognoScan database, Kaplan-Meier plotter, and R2: Kaplan-Meier scanner.
UNASSIGNED: CTLA4 was highly expressed in BRCA tumor tissue compared to normal tissue (P < 0.01). The CTLA4 messenger RNA levels in BRCA based on BRCA subtypes of Luminal, human epidermal growth factor receptor 2, and triple-negative BRCA were considerably higher than in normal tissues (P < 0.001). However, the overexpression of CTLA4 was associated with a better prognosis in BRCA (P < 0.001) and was correlated with clinicopathological characteristics including age, T stage, estrogen receptors, progesterone receptors, and prediction analysis of microarray 50 (P < 0.01). The infiltration of multiple immune cells was associated with increased CTLA4 expression in BRCA (P < 0.001). CTLA4 was highly enriched in antigen binding, immunoglobulin complexes, lymphocyte-mediated immunity, and cytokine-cytokine receptor interaction.
UNASSIGNED: This study provides suggestive evidence of the prognostic role of CTLA4 in BRCA, which may be a therapeutic target for BRCA. Furthermore, CTLA4 may influence BRCA prognosis through antigen binding, immunoglobulin complexes, lymphocyte-mediated immunity, and cytokine-cytokine receptor interaction. These findings help us understand how CTLA4 plays a role in BRCA and set the stage for more research.
UNASSIGNED: We assessed the effect of CTLA4 expression on BRCA using a variety of bioinformatics platforms, including Oncomine, GEPIA, UALCAN, PrognoScan database, Kaplan-Meier plotter, and R2: Kaplan-Meier scanner.
UNASSIGNED: CTLA4 was highly expressed in BRCA tumor tissue compared to normal tissue (P < 0.01). The CTLA4 messenger RNA levels in BRCA based on BRCA subtypes of Luminal, human epidermal growth factor receptor 2, and triple-negative BRCA were considerably higher than in normal tissues (P < 0.001). However, the overexpression of CTLA4 was associated with a better prognosis in BRCA (P < 0.001) and was correlated with clinicopathological characteristics including age, T stage, estrogen receptors, progesterone receptors, and prediction analysis of microarray 50 (P < 0.01). The infiltration of multiple immune cells was associated with increased CTLA4 expression in BRCA (P < 0.001). CTLA4 was highly enriched in antigen binding, immunoglobulin complexes, lymphocyte-mediated immunity, and cytokine-cytokine receptor interaction.
UNASSIGNED: This study provides suggestive evidence of the prognostic role of CTLA4 in BRCA, which may be a therapeutic target for BRCA. Furthermore, CTLA4 may influence BRCA prognosis through antigen binding, immunoglobulin complexes, lymphocyte-mediated immunity, and cytokine-cytokine receptor interaction. These findings help us understand how CTLA4 plays a role in BRCA and set the stage for more research.
摘要：
■细胞毒性T淋巴细胞相关蛋白4（CTLA4）参与各种癌症的进展，但其在乳腺癌（BRCA）中的生物学作用尚不清楚。因此,我们进行了系统的多体分析，以阐述CTLA4在BRCA中的预后价值和潜在机制。
■我们使用多种生物信息学平台评估了CTLA4表达对BRCA的影响，包括Oncomine,GEPIA,UALCAN,PrognoScan数据库,卡普兰-迈耶绘图仪,R2：Kaplan-Meier扫描仪。
■CTLA4在BRCA肿瘤组织中表达高于正常组织(P<0.01)。BRCA中的CTLA4信使RNA水平基于管腔的BRCA亚型，人表皮生长因子受体2和三阴性BRCA显著高于正常组织(P<0.001)。然而,CTLA4的过度表达与BRCA患者预后较好相关(P<0.001),且与患者年龄等临床病理特征相关,T级,雌激素受体，孕激素受体,和预测分析微阵列50(P<0.01)。多种免疫细胞的浸润与BRCA中CTLA4表达增加有关(P<0.001)。CTLA4在抗原结合方面高度富集，免疫球蛋白复合物，淋巴细胞介导的免疫，和细胞因子-细胞因子受体相互作用。
■这项研究为CTLA4在BRCA中的预后作用提供了暗示性证据，这可能是BRCA的治疗靶标。此外，CTLA4可能通过抗原结合影响BRCA预后，免疫球蛋白复合物，淋巴细胞介导的免疫，和细胞因子-细胞因子受体相互作用。这些发现帮助我们了解CTLA4如何在BRCA中发挥作用，并为更多研究奠定基础。
■我们使用多种生物信息学平台评估了CTLA4表达对BRCA的影响，包括Oncomine,GEPIA,UALCAN,PrognoScan数据库,卡普兰-迈耶绘图仪,R2：Kaplan-Meier扫描仪。
■CTLA4在BRCA肿瘤组织中表达高于正常组织(P<0.01)。BRCA中的CTLA4信使RNA水平基于管腔的BRCA亚型，人表皮生长因子受体2和三阴性BRCA显著高于正常组织(P<0.001)。然而,CTLA4的过度表达与BRCA患者预后较好相关(P<0.001),且与患者年龄等临床病理特征相关,T级,雌激素受体，孕激素受体,和预测分析微阵列50(P<0.01)。多种免疫细胞的浸润与BRCA中CTLA4表达增加有关(P<0.001)。CTLA4在抗原结合方面高度富集，免疫球蛋白复合物，淋巴细胞介导的免疫，和细胞因子-细胞因子受体相互作用。
■这项研究为CTLA4在BRCA中的预后作用提供了暗示性证据，这可能是BRCA的治疗靶标。此外，CTLA4可能通过抗原结合影响BRCA预后，免疫球蛋白复合物，淋巴细胞介导的免疫，和细胞因子-细胞因子受体相互作用。这些发现帮助我们了解CTLA4如何在BRCA中发挥作用，并为更多研究奠定基础。
